JP2019508408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508408A5 JP2019508408A5 JP2018541252A JP2018541252A JP2019508408A5 JP 2019508408 A5 JP2019508408 A5 JP 2019508408A5 JP 2018541252 A JP2018541252 A JP 2018541252A JP 2018541252 A JP2018541252 A JP 2018541252A JP 2019508408 A5 JP2019508408 A5 JP 2019508408A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- poly
- ethylene
- antibody
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001225 therapeutic effect Effects 0.000 claims 26
- 239000002105 nanoparticle Substances 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 12
- 229920001223 polyethylene glycol Polymers 0.000 claims 11
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 6
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 230000006023 anti-tumor response Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293617P | 2016-02-10 | 2016-02-10 | |
| US62/293,617 | 2016-02-10 | ||
| PCT/IB2017/050762 WO2017137953A1 (en) | 2016-02-10 | 2017-02-10 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508408A JP2019508408A (ja) | 2019-03-28 |
| JP2019508408A5 true JP2019508408A5 (OSRAM) | 2020-03-19 |
Family
ID=58159116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541252A Withdrawn JP2019508408A (ja) | 2016-02-10 | 2017-02-10 | 治療剤を含む治療用ナノ粒子ならびにそれを作製および使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210188979A1 (OSRAM) |
| EP (1) | EP3413918A1 (OSRAM) |
| JP (1) | JP2019508408A (OSRAM) |
| KR (1) | KR20180101462A (OSRAM) |
| CN (1) | CN108778340A (OSRAM) |
| AU (1) | AU2017218767A1 (OSRAM) |
| BR (1) | BR112018014998A2 (OSRAM) |
| CA (1) | CA3013880A1 (OSRAM) |
| MX (1) | MX2018009723A (OSRAM) |
| RU (1) | RU2018129118A (OSRAM) |
| WO (1) | WO2017137953A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190160139A1 (en) * | 2017-09-13 | 2019-05-30 | Massachusetts Institute Of Technology | Genotype-directed local delivery of targeted therapeutics |
| WO2020030954A1 (en) * | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
| US20230086800A1 (en) * | 2020-03-06 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells |
| GB202103785D0 (en) * | 2021-03-18 | 2021-05-05 | UCB Biopharma SRL | Formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20050042298A1 (en) * | 2003-08-20 | 2005-02-24 | Pardridge William M. | Immunonanoparticles |
| US8206747B2 (en) * | 2008-06-16 | 2012-06-26 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| TR201906255T4 (tr) * | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
| AU2015279738A1 (en) * | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
-
2017
- 2017-02-10 CN CN201780019305.9A patent/CN108778340A/zh active Pending
- 2017-02-10 US US16/074,359 patent/US20210188979A1/en not_active Abandoned
- 2017-02-10 MX MX2018009723A patent/MX2018009723A/es unknown
- 2017-02-10 CA CA3013880A patent/CA3013880A1/en not_active Abandoned
- 2017-02-10 BR BR112018014998A patent/BR112018014998A2/pt not_active IP Right Cessation
- 2017-02-10 RU RU2018129118A patent/RU2018129118A/ru not_active Application Discontinuation
- 2017-02-10 EP EP17707118.0A patent/EP3413918A1/en not_active Withdrawn
- 2017-02-10 KR KR1020187022677A patent/KR20180101462A/ko not_active Ceased
- 2017-02-10 AU AU2017218767A patent/AU2017218767A1/en not_active Abandoned
- 2017-02-10 JP JP2018541252A patent/JP2019508408A/ja not_active Withdrawn
- 2017-02-10 WO PCT/IB2017/050762 patent/WO2017137953A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11931465B2 (en) | Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof | |
| JP2019508408A5 (OSRAM) | ||
| Kaur et al. | Surfactant-based drug delivery systems for treating drug-resistant lung cancer | |
| WO2011079279A3 (en) | Nanoconjugates and nanoconjugate formulations | |
| Welte et al. | Interleukin‐17 could promote breast cancer progression at several stages of the disease | |
| JP2009527566A5 (OSRAM) | ||
| HRP20231504T1 (hr) | Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati | |
| JP2017036323A5 (OSRAM) | ||
| WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
| FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
| EP3875269A4 (en) | LAYERED PRODUCT HAVING AN ETHYLENE ALPHA OLEFIN NON-CONJUGATED POLYEN COPOLYMER COMPOSITION AND USE THEREOF | |
| EA200901451A1 (ru) | Самособирающиеся амфифильные полимеры в качестве противоопухолевых средств | |
| WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
| WO2018134691A3 (en) | Cell surface conjugates and related cell compositions and methods | |
| WO2012040623A3 (en) | Nanostructured gels capable of controlled release of encapsulated agents | |
| WO2011057225A3 (en) | Self-assembled particles from zwitterionic polymers and related methods | |
| JP2017535581A5 (OSRAM) | ||
| Reljic et al. | Mucosal vaccination against tuberculosis using inert bioparticles | |
| WO2015027054A3 (en) | Telodendrimers and nanocarriers and methods of using same | |
| JP2016529286A5 (OSRAM) | ||
| JP2007524613A5 (OSRAM) | ||
| JP2019537600A5 (OSRAM) | ||
| JP2007532685A5 (OSRAM) | ||
| RU2018129118A (ru) | Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения | |
| JP2015528405A5 (OSRAM) |